Neurotech bounces back from FDA rejection with new NTI164 baseline study
Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching a NTI164 baseline data study.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online